DIMERIX EXCLUSIVELY LICENSES DMX-200 IN GREATER CHINA, SOUTH KOREA AND SOUTHEAST ASIA TO EVEREST MEDICINES
- Written by: Business Daily Media
- Everest Medicines licenses exclusive rights to commercialise DMX-200 for the treatment of Focal Segmental Glomerulosclerosis (FSGS) in Greater China, South Korea and Southeast Asia
- 500,000-1 million people are estimated to be living with FSGS in the territories[1]
- Dimerix eligible to receive upfront and potential success-based milestone payments of up to ~AU$481[2] million, plus royalties
- US$10 million (~AU$14.1 million2) upfront payment
- Up to US$330 million (~AU$467 million2) in potential milestone payments
- Tiered royalties on net sales
- Everest is the fifth license deal executed for DMX-200 following the license deals with Advanz Pharma (announced October 2023)[3], Taiba Rare (announced May 2024)[4], Fuso Pharmaceutical Industries (announced 7 January 2025)[5], and Amicus Therapeutics (announced 1 May 2025, now BioMarin)[6]; with over AU$65 million having been received prior to the Everest transaction
- Collectively across the 5 transactions, Dimerix may be eligible to receive up to ~AU$1.9 billion[7] in aggregate total upfront and potential milestone payments, plus additional royalties on net sales
- DMX-200 is in a pivotal Phase 3 trial for FSGS, a rare and serious kidney disease with no approved therapies across these regions
- The ACTION3 Phase 3 clinical trial is fully recruited, with patients enrolled across 21 countries, including Chinese mainland, Hong Kong SAR, Taiwan region, Thailand and Malaysia
- Everest will leverage its specialty kidney disease expertise and commercial platform to register and commercialise DMX-200, offering greater patient access to the growing Asian markets
- Dimerix retains all rights to DMX-200 in all other unlicensed territories
MELBOURNE, Australia, June 16, 2026 /PRNewswire/ -- Dimerix Limited (ASX: DXB, "Dimerix") today announced that it has entered into an exclusive license agreement with Everest Medicines for the commercialisation of Dimerix's Phase 3 drug candidate DMX-200 for all indications including FSGS, in Greater China (Chinese mainland, Hong Kong SAR, Macao SAR and Taiwan region), South Korea and certain Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam and Philippines).
